Testosterone and cardiovascular disease

Open Cardiovascular Medicine Journal

Volumn 10, Issue , 2016, Pages 1-10

  Tambo, Amos ^a   Roshan, Mohsin H K ^a   Pace, Nikolai P ^a  

^a UNIVERSITY OF MALTA   (Malta)

Author keywords

Atherosclerosis; Cardiovascular disease; Hypogonadism; Testosterone; Vascular biology

Indexed keywords

FULVESTRANT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; N(G) NITROARGININE METHYL ESTER; NITROPRUSSIDE SODIUM; PROSTACYCLIN; PROSTAGLANDIN; SEROTONIN; TESTOSTERONE;

ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; GENDER; HEART PROTECTION; HUMAN; HYPOGONADISM; INCIDENCE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TREADMILL EXERCISE; VASOCONSTRICTION; VASODILATATION;

EID: 84971657329     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401610010001     Document Type: Article

References (62)

1. World Health Organization (WHO). Global status report on noncommunicable diseases 2014. 2014; 1-302. Available at: http://www.who.int/nmh/publications/ncd-status-report-2014/en/
2. Celermajer DS, Ayer JG. Childhood risk factors for adult cardiovascular disease and primary prevention in childhood. Heart 2006; 92(11): 1701-6. [http://dx.doi.org/10.1136/hrt.2005.081760] [PMID: 17041125]
3. Fairweather D, Petri MA, Coronado MJ, Cooper LT. Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis. Expert Rev Clin Immunol 2012; 8(3): 269-84. [http://dx.doi.org/10.1586/eci.12.10] [PMID: 22390491]
4. Oskui PM, French WJ, Herring MJ, Mayeda GS, Burstein S, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc 2013; 2(6): e000272. [http://dx.doi.org/10.1161/JAHA.113.000272] [PMID: 24242682]
5. Nakashima Y, Wight TN, Sueishi K. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res 2008; 79(1): 14-23. [http://dx.doi.org/10.1093/cvr/cvn099] [PMID: 18430750]
6. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998; 9(5): 471-4. [http://dx.doi.org/10.1097/00041433-199810000-00012] [PMID: 9812202]
7. Hevonoja T, Pentikäinen MO, Hyvönen MT, Kovanen PT, Ala-Korpela M. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta 2000; 1488(3): 189-210. [http://dx.doi.org/10.1016/S1388-1981(00)00123-2] [PMID: 11082530]
8. Samson S, Mundkur L, Kakkar VV. Immune response to lipoproteins in atherosclerosis. Cholesterol 2012; 2012: 571846 [http://dx.doi.org/10.1155/2012/571846]
9. Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93(7): 1354-63. [http://dx.doi.org/10.1161/01.CIR.93.7.1354] [PMID: 8641024]
10. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90(2): 775-8. [http://dx.doi.org/10.1161/01.CIR.90.2.775] [PMID: 8044947]
11. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352(16): 1685-95. [http://dx.doi.org/10.1056/NEJMra043430] [PMID: 15843671]
12. Mendis S, Thygesen K, Kuulasmaa K, et al. World Health Organization definition of myocardial infarction: 2008-09 revision. Int J Epidemiol 2011; 40(1): 139-46. [http://dx.doi.org/10.1093/ije/dyq165] [PMID: 20926369]
13. Townsend N, Wickramasinghe K, Bhatnagar P, et al. Coronary heart disease statistics. London, England: British Heart Foundation 2012.
14. Hou JW, Collins DC, Schleicher RL. Sources of cholesterol for testosterone biosynthesis in murine Leydig cells. Endocrinology 1990; 127(5): 2047-55. [http://dx.doi.org/10.1210/endo-127-5-2047] [PMID: 2226298]
15. Zouboulis CC, Degitz K. Androgen action on human skin-from basic research to clinical significance. Exp Dermatol 2004; 13(Suppl. 4): 5-10. [http://dx.doi.org/10.1111/j.1600-0625.2004.00255.x] [PMID: 15507105]
16. Xing Y, Edwards MA, Ahlem C, et al. The effects of ACTH on steroid metabolomic profiles in human adrenal cells. J Endocrinol 2011; 209(3): 327-35. [http://dx.doi.org/10.1530/JOE-10-0493] [PMID: 21429963]
17. Finkelstein JS, Yu EW, Burnett-Bowie SA. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013; 369(25): 2457. [PMID: 24350954]
18. Young JM, McNeilly AS. Theca: the forgotten cell of the ovarian follicle. Reproduction 2010; 140(4): 489-504. [http://dx.doi.org/10.1530/REP-10-0094] [PMID: 20628033]
19. Jin JM, Yang WX. Molecular regulation of hypothalamus-pituitary-gonads axis in males. Gene 2014; 551(1): 15-25. [http://dx.doi.org/10.1016/j.gene.2014.08.048] [PMID: 25168889]
20. Keenan DM, Veldhuis JD. Divergent gonadotropin-gonadal dose-responsive coupling in healthy young and aging men. Am J Physiol Regul Integr Comp Physiol 2004; 286(2): R381-9. [http://dx.doi.org/10.1152/ajpregu.00376.2003] [PMID: 14592930]
21. Veldhuis JD, Keenan DM, Liu PY, Iranmanesh A, Takahashi PY, Nehra AX. The aging male hypothalamic-pituitary-gonadal axis: pulsatility and feedback. Mol Cell Endocrinol 2009; 299(1): 14-22. [http://dx.doi.org/10.1016/j.mce.2008.09.005] [PMID: 18838102]
22. Pasquali R. The hypothalamic-pituitary-adrenal axis and sex hormones in chronic stress and obesity: pathophysiological and clinical aspects. Ann N Y Acad Sci 2012; 1264: 20-35. [http://dx.doi.org/10.1111/j.1749-6632.2012.06569.x] [PMID: 22612409]
23. Matsumoto T, Sakari M, Okada M, et al. The androgen receptor in health and disease. Annu Rev Physiol 2013; 75: 201-24. [http://dx.doi.org/10.1146/annurev-physiol-030212-183656] [PMID: 23157556]
24. Bain J. Testosterone and the aging male: to treat or not to treat? Maturitas 2010; 66(1): 16-22. [http://dx.doi.org/10.1016/j.maturitas.2010.01.009] [PMID: 20153946]
25. Sinha-Hikim I, Cornford M, Gaytan H, Lee ML, Bhasin S. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metab 2006; 91(8): 3024-33. [http://dx.doi.org/10.1210/jc.2006-0357] [PMID: 16705073]
26. Tivesten A, Movérare-Skrtic S, Chagin A, et al. Additive protective effects of estrogen and androgen treatment on trabecular bone in ovariectomized rats. J Bone Miner Res 2004; 19(11): 1833-9. [http://dx.doi.org/10.1359/JBMR.040819] [PMID: 15476584]
27. Davey RA, Morris HA. Effects of estradiol and dihydrotestosterone on osteoblast gene expression in osteopenic ovariectomized rats. J Bone Miner Metab 2005; 23(3): 212-8. [http://dx.doi.org/10.1007/s00774-004-0586-z] [PMID: 15838623]
28. Ferrucci L, Maggio M, Bandinelli S, et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 2006; 166(13): 1380-8. [http://dx.doi.org/10.1001/archinte.166.13.1380] [PMID: 16832003]
29. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60(11): 1451-7. [http://dx.doi.org/10.1093/gerona/60.11.1451] [PMID: 16339333]
30. Pope HG Jr, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160(1): 105-11. [http://dx.doi.org/10.1176/appi.ajp.160.1.105] [PMID: 12505808]
31. Azad N, Pitale S, Barnes WE, Friedman N. Testosterone treatment enhances regional brain perfusion in hypogonadal men. J Clin Endocrinol Metab 2003; 88(7): 3064-8. [http://dx.doi.org/10.1210/jc.2002-020632] [PMID: 12843144]
32. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95(6): 2536-59. [http://dx.doi.org/10.1210/jc.2009-2354] [PMID: 20525905]
33. Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med 2011; 124(7): 578-87. [http://dx.doi.org/10.1016/j.amjmed.2010.12.027] [PMID: 21683825]
34. Haring R, Völzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010; 31(12): 1494-501. [http://dx.doi.org/10.1093/eurheartj/ehq009] [PMID: 20164245]
35. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116(23): 2694-701. [http://dx.doi.org/10.1161/CIRCULATIONAHA.107.719005] [PMID: 18040028]
36. Smith GD, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation 2005; 112(3): 332-40. [http://dx.doi.org/10.1161/CIRCULATIONAHA.104.489088] [PMID: 16009799]
37. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89(12): 5920-6. [http://dx.doi.org/10.1210/jc.2003-031719] [PMID: 15579737]
38. Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol 2013; 217(3): R47-71. [http://dx.doi.org/10.1530/JOE-12-0582] [PMID: 23549841]
39. Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab 2010; 21(8): 496-503. [http://dx.doi.org/10.1016/j.tem.2010.03.002] [PMID: 20381374]
40. Arnlöv J, Pencina MJ, Amin S, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med 2006; 145(3): 176-84. [http://dx.doi.org/10.7326/0003-4819-145-3-200608010-00005] [PMID: 16880459]
41. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000; 102(16): 1906-11. [http://dx.doi.org/10.1161/01.CIR.102.16.1906] [PMID: 11034937]
42. Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99(13): 1666-70. [http://dx.doi.org/10.1161/01.CIR.99.13.1666] [PMID: 10190874]
43. Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease 1999; 83(3): 437-439, A9. [http://dx.doi.org/10.1016/S0002-9149(98)00880-7]
44. Herring MJ, Oskui PM, Hale SL, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the basic science literature. J Am Heart Assoc 2013; 2(4): e000271. [http://dx.doi.org/10.1161/JAHA.113.000271] [PMID: 23842280]
45. Deenadayalu VP, White RE, Stallone JN, Gao X, Garcia AJ. Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol 2001; 281(4): H1720-7. [PMID: 11557563]
46. Jones RD, English KM, Jones TH, Channer KS. Testosterone-induced coronary vasodilatation occurs via a non-genomic mechanism: evidence of a direct calcium antagonism action. Clin Sci 2004; 107(2): 149-58. [http://dx.doi.org/10.1042/CS20030386] [PMID: 14992681]
47. Ammar EM, Said SA, Hassan MS. Enhanced vasoconstriction and reduced vasorelaxation induced by testosterone and nandrolone in hypercholesterolemic rabbits. Pharmacol Res 2004; 50(3): 253-9. [http://dx.doi.org/10.1016/j.phrs.2004.03.010] [PMID: 15225667]
48. Ceballos G, Figueroa L, Rubio I, et al. Acute and nongenomic effects of testosterone on isolated and perfused rat heart. J Cardiovasc Pharmacol 1999; 33(5): 691-7. [http://dx.doi.org/10.1097/00005344-199905000-00003] [PMID: 10226854]
49. Tsang S, Wu S, Liu J, Wong TM. Testosterone protects rat hearts against ischaemic insults by enhancing the effects of α(1)-adrenoceptor stimulation. Br J Pharmacol 2008; 153(4): 693-709. [http://dx.doi.org/10.1038/sj.bjp.0707624] [PMID: 18157169]
50. Crouse JR III, Craven TE, Hagaman AP, Bond MG. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation 1995; 92(5): 1141-7. [http://dx.doi.org/10.1161/01.CIR.92.5.1141] [PMID: 7648658]
51. Demirbag R, Yilmaz R, Ulucay A, Unlu D. The inverse relationship between thoracic aortic intima media thickness and testosterone level. Endocr Res 2005; 31(4): 335-44. [http://dx.doi.org/10.1080/07435800500449494] [PMID: 16433252]
52. Maturana MA, Breda V, Lhullier F, Spritzer PM. Relationship between endogenous testosterone and cardiovascular risk in early postmenopausal women. Metabolism 2008; 57(7): 961-5. [http://dx.doi.org/10.1016/j.metabol.2008.02.012] [PMID: 18555838]
53. Patel SM, Ratcliffe SJ, Reilly MP, et al. Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2009; 94(12): 4776-84. [http://dx.doi.org/10.1210/jc.2009-0740] [PMID: 19846742]
54. Rohr UD. The impact of testosterone imbalance on depression and women's health. Maturitas 2002; 41(Suppl. 1): S25-46. [http://dx.doi.org/10.1016/S0378-5122(02)00013-0] [PMID: 11955793]
55. Yasui T, Matsui S, Tani A, Kunimi K, Yamamoto S, Irahara M. Androgen in postmenopausal women. J Med Invest 2012; 59(1-2): 12-27. [http://dx.doi.org/10.2152/jmi.59.12] [PMID: 22449989]
56. Wakasugi M, Noguchi T, Kazama YI, Kanemaru Y, Onaya T. The effects of sex hormones on the synthesis of prostacyclin (PGI2) by vascular tissues. Prostaglandins 1989; 37(4): 401-10. [http://dx.doi.org/10.1016/0090-6980(89)90090-7] [PMID: 2669031]
57. Nettleship JE, Jones TH, Channer KS, Jones RD. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation 2007; 116(21): 2427-34. [http://dx.doi.org/10.1161/CIRCULATIONAHA.107.708768] [PMID: 17984376]
58. Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 2011; 34(7): 1669-75. [http://dx.doi.org/10.2337/dc10-2339] [PMID: 21709300]
59. Pasquali R, Casimirri F, De Iasio R, et al. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J Clin Endocrinol Metab 1995; 80(2): 654-8. [PMID: 7852532]
60. Schrör K, Morinelli TA, Masuda A, Matsuda K, Mathur RS, Halushka PV. Testosterone treatment enhances thromboxane A2 mimetic induced coronary artery vasoconstriction in guinea pigs. Eur J Clin Invest 1994; 24(Suppl. 1): 50-2. [http://dx.doi.org/10.1111/j.1365-2362.1994.tb02428.x] [PMID: 8013532]
61. Shapiro J, Christiana J, Frishman WH. Testosterone and other anabolic steroids as cardiovascular drugs. Am J Ther 1999; 6(3): 167-74. [http://dx.doi.org/10.1097/00045391-199905000-00008] [PMID: 10423660]
62. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310(17): 1829-36. [http://dx.doi.org/10.1001/jama.2013.280386] [PMID: 24193080]